热门资讯> 正文

Inhibrx Biosciences GAAP每股收益为-2.15美元

2026-05-15 04:46

Inhibrx Biosciences press release (INBX): Q1 GAAP EPS of -$2.15.
Cash and Cash Equivalents. As of March 31, 2026, the Company had cash and cash equivalents of $161.7 million, as compared to $124.2 million as of December 31, 2025. The Company's cash balance increased as a result of the receipt of gross proceeds of $75.0 million in March 2026 upon entering into the First Amendment to the Loan and Security Agreement (March 2026 Amendment) with Oxford Finance LLC (Oxford).

More on Inhibrx Biosciences

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue
Inhibrx Biosciences FY25 Review: Catalyst-Driven Hold Ahead Of Key 2026 Data
Inhibrx rises on upcoming interim mid-stage data for head and neck cancer asset
Inhibrx cancer drug reportedly drawing interest of Merck and rivals
Seeking Alpha’s Quant Rating on Inhibrx Biosciences

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。